MedTrace Logo

PRISM Registry: Pseudobulbar Affect Registry Series

NCT01366027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5290

Last updated 2014-04-16

No results posted yet for this study

Summary

PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated.

The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including

* Alzheimer's disease
* Amyotrophic lateral sclerosis
* Multiple sclerosis
* Parkinson's disease
* Stroke
* Traumatic brain injury

Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.

Conditions

Sponsors & Collaborators

  • Avanir Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Randall Kaye, MD · Avanir Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01366027 on ClinicalTrials.gov